Novel Coronavirus (COVID-19) Vaccine Market, Global Outlook and Forecast 2022-2028

March 2022 | 107 pages | ID: NBAD97F3CB94EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Novel Coronavirus (COVID-19) Vaccine in Global, including the following market information:

Global Novel Coronavirus (COVID-19) Vaccine Market Size 2023-2028, ($ millions)

The global Novel Coronavirus (COVID-19) Vaccine market is projected to reach US$ million by 2028.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Novel Coronavirus (COVID-19) Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Novel Coronavirus (COVID-19) Vaccine Market, by Type, 2023-2028 ($ millions)

Global Novel Coronavirus (COVID-19) Vaccine Market Segment Percentages, by Type

• DNA
• RNA
• Others

Global Novel Coronavirus (COVID-19) Vaccine Market, by Application, 2023-2028 ($ millions)

Global Novel Coronavirus (COVID-19) Vaccine Market Segment Percentages, by Application

• Mild Symptom Patient
• Critically Ill Patient

Global Novel Coronavirus (COVID-19) Vaccine Market, By Region and Country, 2023-2028 ($ Millions)

Global Novel Coronavirus (COVID-19) Vaccine Market Segment Percentages, By Region and Country

• United States
• Europe
• Asia
• China
• Rest of World

Competitor Analysis

The report also provides analysis of leading market participants including:

Further, the report presents profiles of competitors in the market, key players include:

• Inovio Pharmaceuticals
• Takis Biotech (Evvivax)
• Zydus Cadila
• Codagenix, Inc.
• GeoVax, Inc.
• Bravovax
• Janssen Pharmaceutical Companies
• Altimmune
• Vaxart
• CanSino Biologics
• ExpreS2ion Biotechnologies ApS
• Clover Biopharmaceuticals
• GSK
• Vaxil Bio Ltd.
• Generex
• Novavax, Inc.
• Sanofi Pasteur
• Baylor
• iBio, Inc.
• Moderna, Inc.
• Curevac
• ImmunoPrecise

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Novel Coronavirus (COVID-19) Vaccine Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Novel Coronavirus (COVID-19) Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NOVEL CORONAVIRUS (COVID-19) VACCINE OVERALL MARKET SIZE

2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size: 2022 VS 2028
2.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size, Prospects & Forecasts: 2022-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Key Novel Coronavirus (COVID-19) Vaccine Players in Global Market
3.2 Global Companies Novel Coronavirus (COVID-19) Vaccine Product & Technology

4 PLAYERS PROFILES

4.1 Inovio Pharmaceuticals
  4.1.1 Inovio Pharmaceuticals Corporate Summary
  4.1.2 Inovio Pharmaceuticals Business Overview
  4.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.1.4 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.2 Takis Biotech (Evvivax)
  4.2.1 Takis Biotech (Evvivax) Corporate Summary
  4.2.2 Takis Biotech (Evvivax) Business Overview
  4.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.2.4 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.3 Zydus Cadila
  4.3.1 Zydus Cadila Corporate Summary
  4.3.2 Zydus Cadila Business Overview
  4.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.3.4 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.4 Codagenix, Inc.
  4.4.1 Codagenix, Inc. Corporate Summary
  4.4.2 Codagenix, Inc. Business Overview
  4.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.4.4 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.5 GeoVax, Inc.
  4.5.1 GeoVax, Inc. Corporate Summary
  4.5.2 GeoVax, Inc. Business Overview
  4.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.5.4 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.6 Bravovax
  4.6.1 Bravovax Corporate Summary
  4.6.2 Bravovax Business Overview
  4.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.6.4 Bravovax Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.7 Janssen Pharmaceutical Companies
  4.7.1 Janssen Pharmaceutical Companies Corporate Summary
  4.7.2 Janssen Pharmaceutical Companies Business Overview
  4.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.7.4 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.8 Altimmune
  4.8.1 Altimmune Corporate Summary
  4.8.2 Altimmune Business Overview
  4.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.8.4 Altimmune Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.9 Vaxart
  4.9.1 Vaxart Corporate Summary
  4.9.2 Vaxart Business Overview
  4.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.9.4 Vaxart Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.10 CanSino Biologics
  4.10.1 CanSino Biologics Corporate Summary
  4.10.2 CanSino Biologics Business Overview
  4.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.10.4 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.11 ExpreS2ion Biotechnologies ApS
  4.11.1 ExpreS2ion Biotechnologies ApS Corporate Summary
  4.11.2 ExpreS2ion Biotechnologies ApS Business Overview
  4.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.11.4 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.12 Clover Biopharmaceuticals
  4.12.1 Clover Biopharmaceuticals Corporate Summary
  4.12.2 Clover Biopharmaceuticals Business Overview
  4.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.12.4 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.13 GSK
  4.13.1 GSK Corporate Summary
  4.13.2 GSK Business Overview
  4.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.13.4 GSK Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.14 Vaxil Bio Ltd.
  4.14.1 Vaxil Bio Ltd. Corporate Summary
  4.14.2 Vaxil Bio Ltd. Business Overview
  4.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.14.4 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.15 Generex
  4.15.1 Generex Corporate Summary
  4.15.2 Generex Business Overview
  4.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.15.4 Generex Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.16 Novavax, Inc.
  4.16.1 Novavax, Inc. Corporate Summary
  4.16.2 Novavax, Inc. Business Overview
  4.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.16.4 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.17 Sanofi Pasteur
  4.17.1 Sanofi Pasteur Corporate Summary
  4.17.2 Sanofi Pasteur Business Overview
  4.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.17.4 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.18 Baylor
  4.18.1 Baylor Corporate Summary
  4.18.2 Baylor Business Overview
  4.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.18.4 Baylor Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.19 iBio, Inc.
  4.19.1 iBio, Inc. Corporate Summary
  4.19.2 iBio, Inc. Business Overview
  4.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.19.4 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.20 Moderna, Inc.
  4.20.1 Moderna, Inc. Corporate Summary
  4.20.2 Moderna, Inc. Business Overview
  4.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.20.4 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.21 Curevac
  4.21.1 Curevac Corporate Summary
  4.21.2 Curevac Business Overview
  4.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.21.4 Curevac Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
4.22 ImmunoPrecise
  4.22.1 ImmunoPrecise Corporate Summary
  4.22.2 ImmunoPrecise Business Overview
  4.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
  4.22.4 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

5 SIGHTS BY REGION

5.1 By Region - Global Novel Coronavirus (COVID-19) Vaccine Market Size, 2023 & 2028
5.2 By Region - Global Novel Coronavirus (COVID-19) Vaccine Revenue, (2023-2028)
5.3 United States
  5.3.1 Key Players of Novel Coronavirus (COVID-19) Vaccine in United States
  5.3.2 United States Novel Coronavirus (COVID-19) Vaccine Development Current Situation and Forecast
5.4 Europe
  5.4.1 Key Players of Novel Coronavirus (COVID-19) Vaccine in Europe
  5.4.2 Europe Novel Coronavirus (COVID-19) Vaccine Development Current Situation and Forecast
5.5 China
  5.5.1 Key Players of Novel Coronavirus (COVID-19) Vaccine in China
  5.5.2 China Novel Coronavirus (COVID-19) Vaccine Development Current Situation and Forecast
5.6 Rest of World

6 SIGHTS BY PRODUCT

6.1 by Type - Global Novel Coronavirus (COVID-19) Vaccine Market Size Markets, 2023 & 2028
6.2 DNA
6.3 RNA
6.4 Others

7 SIGHTS BY APPLICATION

7.1 By Application - Global Novel Coronavirus (COVID-19) Vaccine Market Size, 2023 & 2028
7.2 Mild Symptom Patient
7.3 Critically Ill Patient

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Novel Coronavirus (COVID-19) Vaccine Market Opportunities & Trends in Global Market
Table 2. Novel Coronavirus (COVID-19) Vaccine Market Drivers in Global Market
Table 3. Novel Coronavirus (COVID-19) Vaccine Market Restraints in Global Market
Table 4. Key Players of Novel Coronavirus (COVID-19) Vaccine in Global Market
Table 5. Global Companies Novel Coronavirus (COVID-19) Vaccine Product & Technology
Table 6. Inovio Pharmaceuticals Corporate Summary
Table 7. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 8. Takis Biotech (Evvivax) Corporate Summary
Table 9. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 10. Zydus Cadila Corporate Summary
Table 11. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 12. Codagenix, Inc. Corporate Summary
Table 13. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 14. GeoVax, Inc. Corporate Summary
Table 15. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 16. Bravovax Corporate Summary
Table 17. Bravovax Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 18. Janssen Pharmaceutical Companies Corporate Summary
Table 19. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 20. Altimmune Corporate Summary
Table 21. Altimmune Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 22. Vaxart Corporate Summary
Table 23. Vaxart Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 24. CanSino Biologics Corporate Summary
Table 25. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 26. ExpreS2ion Biotechnologies ApS Corporate Summary
Table 27. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 28. Clover Biopharmaceuticals Corporate Summary
Table 29. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 30. GSK Corporate Summary
Table 31. GSK Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 32. Vaxil Bio Ltd. Corporate Summary
Table 33. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 34. Generex Corporate Summary
Table 35. Generex Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 36. Novavax, Inc. Corporate Summary
Table 37. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 38. Sanofi Pasteur Corporate Summary
Table 39. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 40. Baylor Corporate Summary
Table 41. Baylor Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 42. iBio, Inc. Corporate Summary
Table 43. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 44. Moderna, Inc. Corporate Summary
Table 45. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 46. Curevac Corporate Summary
Table 47. Curevac Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 48. ImmunoPrecise Corporate Summary
Table 49. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product Offerings
Table 50. By Region– Global Novel Coronavirus (COVID-19) Vaccine Revenue, (US$, Mn), 2023 & 2028
Table 51. By Region - Global Novel Coronavirus (COVID-19) Vaccine Revenue, (US$, Mn), 2023-2028
Table 52. By Type – Global Novel Coronavirus (COVID-19) Vaccine Market Size, (US$, Mn), 2023 & 2028
Table 53. By Application– Global Novel Coronavirus (COVID-19) Vaccine Market Size, (US$, Mn), 2023 & 2028

List Of Figures

LIST OF FIGURES

Figure 1. Novel Coronavirus (COVID-19) Vaccine Segment by Type in 2021
Figure 2. Novel Coronavirus (COVID-19) Vaccine Segment by Application in 2021
Figure 3. Global Novel Coronavirus (COVID-19) Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size: 2022 VS 2028 (US$, Mn)
Figure 6. Global Novel Coronavirus (COVID-19) Vaccine Revenue, 2017-2028 (US$, Mn)
Figure 7. By Region - Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share, 2023-2028
Figure 8. By Type - Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share, 2023-2028
Figure 9. By Application - Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share, 2023-2028